Coronary Restenosis

07/20/2005 - "Recently, preliminary data of the ORBIT study have been presented; coronary restenosis after oral treatment with sirolimus (SRL) was merely 7.7%. "
12/01/2012 - "Rapamycin (Sirolimus®) is used to prevent rejection of transplanted organs and coronary restenosis. "
11/01/2005 - "To assess the role of oral rapamycin in the prevention of coronary restenosis in patients undergoing coronary stenting. "
06/01/2005 - "Finally, new antiproliferative agents, such as oral rapamycin, have been introduced to reduce the rate of coronary restenosis during follow-up."
05/01/2003 - "Sirolimus in highly effective in preventing kidney allograft acute rejection and in-stent coronary restenosis."

02/01/2019 - "Coronary restenosis is the answer of the arterial wall to a mechanical violation through balloon angioplasty, bare-metal (BM) stent implantation or rotational atherectomy through repeated narrowing. "
04/01/2013 - "Mechanical and Histopathological Comparison between Commercialized and Newly Designed Coronary Bare Metal Stents in a Porcine Coronary Restenosis Model."
12/15/2009 - "Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents."
12/01/2009 - "In spite of all randomized studies with oral therapies in the bare metal stent (BMS) era demonstrating positive reductions in coronary restenosis, this practice has not been introduced clinically. "
09/01/2013 - "In the era of drug-eluting stents (DESs), the ability of clinicians to predict which patients have a low risk of coronary restenosis following bare-metal stent (BMS) implantion is likely to be of benefit. "

05/01/2010 - "The purpose of this study was to evaluate the Genous(TM) endothelial progenitor cell capturing stent vs. the Taxus Liberté paclitaxel-eluting stent in patients with de novo coronary lesions with a high-risk of coronary restenosis. "
03/01/2013 - "[Paclitaxel-coated balloon catheter in coronary restenosis?]."
05/01/2009 - "Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model."
07/01/2007 - "After elective paclitaxel-eluting stent implantation, there is no difference in coronary restenosis in younger and elderly patients, suggesting an age-independent efficacy."
07/01/2007 - "We sought to evaluate the impact of paclitaxel-eluting stents on coronary restenosis in elderly patients undergoing elective PCI. "

11/01/2013 - "The aim of this study was to examine the histolopathogical effects among the biolimus, zotarolimus, and everolimus eluting stent (EES) in the porcine coronary restenosis model. "
10/18/2021 - "Preclinical Evaluation of a Novel Polymer-free Everolimus-eluting Stent in a Mid-term Porcine Coronary Restenosis Model."
11/01/2013 - "Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model."
12/01/2016 - "Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial)."
11/01/2016 - "We sought to evaluate efficacy of a polymer-free DES coated with everolimus using nitrogen-doped TiO2 film deposition in a porcine coronary restenosis model. "

04/04/2006 - "Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio."
12/01/2004 - "A ReoPro-coated stent is safe, and may be effective in the prevention of coronary restenosis."
10/01/2007 - "Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model."
03/07/2006 - "Recently we have demonstrated that abciximab-coated stents have inhibitory effects in the prevention of coronary restenosis. "
12/01/2004 - "Previously, the inhibition of coronary restenosis with Abciximab (ReoPro)-coated stent in a porcine model was reported. "

01/01/2021 - "Moreover, the inhibitory effect of NTM on smooth muscle cell proliferation was not inferior to that of the polymer-based EES with lower fibrin deposition in this porcine coronary restenosis model."
11/01/2016 - "In a porcine model of coronary restenosis, a novel polymer-free DES using nitrogen-doped TiO2 film deposition shows higher biocompatibility and compares favorably with a commercial DES."
01/01/2016 - "Therefore, we evaluate vascular response of a new generation biodegradable polymer SES (BP-SES: Alex Plus, Balton) and fluoropolymer EES (EES: Xience Pro, Abbott) in the porcine coronary restenosis model. "
10/18/2021 - "Preclinical Evaluation of a Novel Polymer-free Everolimus-eluting Stent in a Mid-term Porcine Coronary Restenosis Model."
11/01/2016 - "We sought to evaluate efficacy of a polymer-free DES coated with everolimus using nitrogen-doped TiO2 film deposition in a porcine coronary restenosis model. "

10/01/2004 - "Patients who consumed > or = 50 g alcohol a week had a lower mean late loss of the luminal diameter (1.1 (0.79) mm v 1.45 (0.82) mm, p = 0.002), a lower rate of coronary restenosis within the stented segment (33.7% v 48.8%, p = 0.001), and a lower rate of repeat angioplasty (23.3% v 42.5%, p = 0.002). "
10/01/2004 - "Mean late loss of luminal diameter, rate of coronary restenosis of 50% or more within the stented segment, and rate of repeat angioplasty. "
09/01/1997 - "To evaluate the early luminal diameter loss in the first 15 min after percutaneous transluminal coronary angioplasty (PTCA) and its influence on coronary restenosis. "
09/01/1995 - "Coronary restenosis was primarily defined as loss of 50% or more of the luminal diameter gain from the procedure. "
12/01/2019 - "In addition, the late luminal loss per stent in the rehabilitation exercise group was significantly smaller than that in the control group ((pooled MD: -0.33, 95% CI: -0.52 to -0.13, p < 0.01); heterogeneity: Chi2=0.27, df =1 (p = 0.60); I2=0%).Conclusions: Appropriate rehabilitation exercise reduces the incidence of coronary restenosis after PCI in patients with CHD and contributes to a significant reduction in late luminal loss in the stented coronary segment.Implications"

01/11/1996 - "These results suggest that tranilast may be effective in preventing coronary restenosis."
06/18/1997 - "These results suggest that tranilast inhibits the contraction of vascular smooth muscle by inhibiting Ca2+ mobilization, which might be related to its preventive effect on coronary restenosis after percutaneous transluminal coronary angioplasty."
06/18/1997 - "Recently, the anti-allergic drug tranilast has been shown to reduce the rate of coronary restenosis after percutaneous transluminal coronary angioplasty. "
04/01/1997 - "In a recent clinical study, tranilast, an anti-allergic agent, was shown to reduce the rate of coronary restenosis after percutaneous transluminal coronary angioplasty, although the mechanism of this effect is unclear. "

10/01/2003 - "The CXCR3 - plasma IP10 chemokine receptor - chemokine interaction on monocytes may affect the development of coronary restenosis, but not de novo stenosis, in patients with CAD."
01/01/2008 - "Although restenosis after successful coronary stenting is associated with changes in adhesion molecules and chemokines, it is unclear whether the differential effects of these molecules between a bare metal stent (BMS) and sirolimus-eluting stent (SES) may help to prevent coronary restenosis. "

11/01/2016 - "In a porcine model of coronary restenosis, a novel polymer-free DES using nitrogen-doped TiO2 film deposition shows higher biocompatibility and compares favorably with a commercial DES."
11/01/2016 - "We sought to evaluate efficacy of a polymer-free DES coated with everolimus using nitrogen-doped TiO2 film deposition in a porcine coronary restenosis model. "
10/18/2021 - "We conducted a mid-term evaluation of a novel polymer-free everolimus-eluting stent using nitrogen-doped titanium dioxide film deposition (TIGEREVOLUTION®) in comparison with a commercial durable polymer everolimus-eluting stent (XIENCE Alpine®) in a porcine coronary restenosis model. "
11/01/2016 - "A novel polymer-free drug-eluting stent coated with everolimus using nitrogen-doped titanium dioxide film deposition in a porcine coronary restenosis model."

06/01/2011 - "Whereas the efficacy of balloon angioplasty was challenged both by immediate mechanical complications and by a high incidence of restenosis, coronary stents offered cardiologists a means by which to not only augment immediate procedural success, but also to reduce the incidence of restenosis following coronary intervention. "
04/01/2009 - "Drug-eluting coronary stent implantation emerged as a safe and effective therapeutic approach by preventing coronary restenosis and reducing the need for further revascularization. "
01/01/2007 - "Coronary restenosis after angioplasty has been reduced by stenting procedure, but in-stent restenosis (ISR) has not been eliminated yet, especially in tortuous vessels. "
01/01/2003 - "The year 2002 was marked elsewhere by imagination after the publication of the RAVEL study on coated stents delivering anti-proliferative drugs in order to avoid coronary restenosis. "
11/01/2002 - "In this study, we have examined the implication of this polymorphism with regard to coronary restenosis after Palmaz-Schatz stent deployment. "

01/01/2017 - "Although the drug-eluting stent (DES) has dramatically reduced the rate of coronary restenosis, it still occurs in up to 20% of patients with a DES. "
07/18/2006 - "The cost-effectiveness ratio for PES in the study population compares reasonably with that for other treatments that reduce coronary restenosis, including alternative drug-eluting stent platforms."
06/28/2005 - "Published rates of coronary restenosis have fallen below 10% in drug-eluting stent trials. "
04/03/2015 - "The drug-eluting stent (DES) decreases the rate of coronary restenosis and re-obstruction. "
07/20/2012 - "The current treatment for coronary restenosis following balloon angioplasty involves the use of a mechanical or drug eluting stent (DES). "

06/12/1997 - "We studied the safety and efficacy of catheter-based intracoronary gamma radiation plus stenting to reduce coronary restenosis in patients with previous restenosis. "
06/01/2000 - "The SCRIPPS trial--catheter-based radiotherapy to inhibit coronary restenosis."
06/12/1997 - "In this preliminary, short-term study of patients with previous coronary restenosis, coronary stenting followed by catheter-based intracoronary radiotherapy substantially reduced the rate of subsequent restenosis."
01/19/1999 - "Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis."
12/01/1997 - "Catheter-based radiotherapy prevented coronary restenosis after stenting in patients with previous restenosis."

01/01/2003 - "Our experience in intravascular radiation therapy for coronary restenosis has provided us the opportunity to explore this treatment strategy for carotid restenosis. "
07/01/2002 - "Prevention of coronary restenosis with radiation therapy: a review."
05/09/2000 - "Prevention of coronary restenosis : the evolving evidence base for radiation therapy."
12/01/1999 - "Early and late effects of radiation treatment for prevention of coronary restenosis: a critical appraisal."
01/01/1998 - "Radiotherapy to inhibit coronary restenosis: kind of a light at the end of the tunnel?"

09/01/2002 - "Although no pharmacologic agent to date has been effective in preventing restenosis, both beta-ray emitters and gamma-ray emitters used in endovascular brachytherapy have been shown to reduce coronary restenosis. "
01/01/1999 - "Therefore, pending completion of long-term clinical studies, caution should be exercised before the widespread use of brachytherapy is advocated for the treatment and prevention of coronary restenosis."
02/01/2003 - "[Brachytherapy for coronary restenosis: state of art in 2003]."
11/01/2001 - "Non-flow limiting dissection leading to late coronary restenosis following intracoronary brachytherapy."
04/12/2001 - "[Clinical and economic aspects of chronic coronary restenosis: potential advantage of intracoronary brachytherapy]."